cPass Neutralization Antibody Detection kit detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.


  • Global patent protection for the kit will be firmly implemented.
  • 96 well ELISA format test with ACE2 protein attached to the plate and HRP labeled RBD is used for detection.
  • Can be used with serum and plasma samples.
  • The kit comes with positive and negative controls.
  • 4 wells are typically used for the controls, so 92 wells can be used for samples.

Watch the cPass video to learn how it works

Placing An Order

covid 19 diagnostics svnt

cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit

Authorization
RUO
Size
96 Test
Quantity
Get A Quote

Features

Species Independent

Isotype Independent

High Specificity

High Sensitivity

Safe & Scalable

Technology

  • Product Introduction

    Dr. Linfa Wang, Ph.D., FTSE, is the director of the Program in Emerging Infectious Diseases at Duke-NUS Medical School in Singapore. His team at Duke-NUS, worked together with Diagnostics Development Hub and GenScript co-developed cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.